Patents by Inventor Dalton Dietrich

Dalton Dietrich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11918659
    Abstract: Described herein are materials and methods for inducing therapeutic hypothermia in a subject in need thereof.
    Type: Grant
    Filed: September 19, 2019
    Date of Patent: March 5, 2024
    Assignee: UNIVERSITY OF MIAMI
    Inventors: Sylvia Daunert, Suzana Hamdan, Dalton Dietrich, Sapna Deo, Helen Bramlett
  • Publication number: 20240060995
    Abstract: An array of inflammatory cytokines are useful as a biomarker of traumatic brain injury, including inflammasome proteins. Biomarker cut-off points, ROC, and other characteristics have been determined.
    Type: Application
    Filed: April 25, 2023
    Publication date: February 22, 2024
    Inventors: Juan Pablo de Rivero Vaccari, Robert W. Keane, W. Dalton Dietrich, Jennifer Christine Munoz-Pareja, Nathan H. Johnson, Jon Perez-Barcena
  • Patent number: 11840565
    Abstract: The compositions and methods described herein include methods and agents that inhibit inflammasome signaling in a mammal such as antibodies directed against inflammasome components used alone or in combination with extracellular vesicle uptake inhibitor(s) or other agents. Also described herein are compositions and methods of use thereof for treating viral-associated lung inflammation, for example lung inflammation associated with viral infections such as SARS-CoV-2.
    Type: Grant
    Filed: November 12, 2021
    Date of Patent: December 12, 2023
    Assignee: UNIVERSITY OF MIAMI
    Inventors: Robert W. Keane, W. Dalton Dietrich, Juan Pablo De Rivero Vaccari, Helen M. Bramlett
  • Publication number: 20230349929
    Abstract: The present invention provides novel markers of the severity of a central nervous system injury, such as spinal cord injury or traumatic brain injury, in a patient. In particular, protein components of inflammasomes in the cerebrospinal fluid that can be used to assess the severity of central nervous system injury in a patient are disclosed. Methods of using such protein biomarkers to determine a prognosis, direct treatment and rehabilitation efforts, and monitor response to treatment for a patient with a central nervous system injury are also described.
    Type: Application
    Filed: July 5, 2023
    Publication date: November 2, 2023
    Inventors: Robert W. KEANE, W. Dalton DIETRICH, Juan Pablo DE RIVERO VACCARI, Stephanie ADAMCZAK, M. Ross BULLOCK, Allan LEVI, Michael Y. WANG
  • Publication number: 20230251273
    Abstract: The present invention provides compositions and methods for detecting components of the inflammasome in a sample from a subject as markers for brain injuries such as multiple sclerosis, stroke or traumatic brain injury. Methods of using such inflammasome markers to determine prognosis, direct treatment and monitor response to treatment for the subject with a brain injury such as multiple sclerosis, stroke, mild cognitive impairment or traumatic brain injury are also described.
    Type: Application
    Filed: July 12, 2022
    Publication date: August 10, 2023
    Inventors: Juan Pablo DE RIVERO VACCARI, Robert W. KEANE, W. Dalton DIETRICH, Helen BRAMLETT
  • Publication number: 20230238030
    Abstract: The present invention provides compositions and methods for reducing inflammation in the lungs of a mammal that is afflicted by a condition that leads to inflammation in the lungs. The compositions and methods described herein include agents that inhibit inflammasome signaling in the mammal such as antibodies directed against inflammasome components used alone or in combination with extracellular vesicle uptake inhibitor(s).
    Type: Application
    Filed: September 23, 2022
    Publication date: July 27, 2023
    Inventors: Robert W. KEANE, W. Dalton DIETRICH, Nadine KERR, Shu WU, Juan Pablo DE RIVERO VACCARI
  • Publication number: 20220169715
    Abstract: The present invention provides compositions and methods for reducing inflammation in the lungs of a mammal that is afflicted by a condition that leads to inflammation in the lungs. The compositions and methods described herein include agents that inhibit inflammasome signaling in the mammal such as antibodies directed against inflammasome components used alone or in combination with extracellular vesicle uptake inhibitor(s).
    Type: Application
    Filed: February 14, 2022
    Publication date: June 2, 2022
    Inventors: Robert W. KEANE, W. Dalton DIETRICH, Nadine KERR, Shu WU, Juan Pablo DE RIVERO VACCARI
  • Publication number: 20220154142
    Abstract: The invention provides a method of producing a population of human Schwann cells. The method comprises (a) incubating human fascicles with one or more mitogens for a priming period of three to fourteen days to produce primed fascicles, (b) incubating the primed fascicles with one or more tissue dissociation enzymes to produce primed Schwann cells, (c) culturing the primed Schwann cells at an initial Po density for a period of time to achieve no greater than 90% confluence, (d) expanding the population of Schwann cells by culturing the Schwann cells at an initial passage density for a period of time to achieve no greater than 90% confluence for at least two passages, and harvesting the population of human Schwann cells. The invention further provides an isolated population of Schwann cells obtained by the method described herein. In various aspects of the invention, the isolated population is provided in a composition.
    Type: Application
    Filed: February 2, 2022
    Publication date: May 19, 2022
    Inventors: Dalton Dietrich, Gagani Athauda, Mary Bunge, James Guest, Allan Levi, Damien Pearse, Patrick Wood, Aisha Khan
  • Publication number: 20220153826
    Abstract: The compositions and methods described herein include methods and agents that inhibit inflammasome signaling in a mammal such as antibodies directed against inflammasome components used alone or in combination with extracellular vesicle uptake inhibitor(s) or other agents. Also described herein are compositions and methods of use thereof for treating viral-associated lung inflammation, for example lung inflammation associated with viral infections such as SARS-CoV-2.
    Type: Application
    Filed: November 12, 2021
    Publication date: May 19, 2022
    Inventors: Robert W. KEANE, W. Dalton DIETRICH, Juan Pablo De Rivero VACCARI, Helen M. BRAMLETT
  • Patent number: 11174307
    Abstract: The compositions and methods described herein include methods and agents that inhibit inflammasome signaling in a mammal such as antibodies directed against inflammasome components used alone or in combination with extracellular vesicle uptake inhibitor(s) or other agents. Also described herein are compositions and methods of use thereof for treating viral-associated lung inflammation, for example lung inflammation associated with viral infections such as SARS-CoV-2.
    Type: Grant
    Filed: April 23, 2020
    Date of Patent: November 16, 2021
    Assignee: UNIVERSITY OF MIAMI
    Inventors: Robert W. Keane, W. Dalton Dietrich, Juan Pablo De Rivero Vaccari, Helen M. Bramlett
  • Publication number: 20210346515
    Abstract: Described herein are materials and methods for inducing therapeutic hypothermia in a subject in need thereof.
    Type: Application
    Filed: September 19, 2019
    Publication date: November 11, 2021
    Inventors: Sylvia Daunert, Suzana Hamdan, Dalton Dietrich, Sapna Deo, Helen Bramlett
  • Publication number: 20210324065
    Abstract: The present invention provides compositions and methods for reducing inflammation in the lungs of a mammal that is afflicted by a condition that leads to inflammation in the lungs. The compositions and methods described herein include agents that inhibit inflammasome signaling in the mammal such as antibodies directed against inflammasome components used alone or in combination with extracellular vesicle uptake inhibitor(s).
    Type: Application
    Filed: June 25, 2021
    Publication date: October 21, 2021
    Inventors: Robert W. KEANE, W. Dalton DIETRICH, Nadine KERR, Shu WU, Juan Pablo DE RIVERO VACCARI
  • Publication number: 20210284723
    Abstract: The compositions and methods described herein include agents that inhibit inflammasome signaling in the mammal such as antibodies directed against inflammasome components used alone or in combination with extracellular vesicle uptake inhibitor(s). Also described herein are compositions and methods of use thereof for treating inflammasome related diseases or conditions.
    Type: Application
    Filed: July 3, 2019
    Publication date: September 16, 2021
    Inventors: Robert W. KEANE, W. Dalton DIETRICH, Juan Pablo DE RIVERO VACCARI, Helen M. BRAMLETT, Roberta BRAMBILLA
  • Patent number: 10961306
    Abstract: The compositions and methods described herein include agents that inhibit inflammasome signaling in the mammal such as antibodies directed against inflammasome components used alone or in combination with extracellular vesicle uptake inhibitor(s). Also described herein are compositions and methods of use thereof for treating multiple sclerosis.
    Type: Grant
    Filed: April 13, 2020
    Date of Patent: March 30, 2021
    Assignee: UNIVERSITY OF MIAMI
    Inventors: Robert W. Keane, W. Dalton Dietrich, Juan Pablo De Rivero Vaccari, Helen M. Bramlett, Roberta Brambilla
  • Publication number: 20200363432
    Abstract: The present invention provides novel markers of the severity of a central nervous system injury, such as spinal cord injury or traumatic brain injury, in a patient. In particular, protein components of inflammasomes in the cerebrospinal fluid that can be used to assess the severity of central nervous system injury in a patient are disclosed. Methods of using such protein biomarkers to determine a prognosis, direct treatment and rehabilitation efforts, and monitor response to treatment for a patient with a central nervous system injury are also described.
    Type: Application
    Filed: August 6, 2020
    Publication date: November 19, 2020
    Inventors: Robert W. KEANE, W. Dalton DIETRICH, Juan Pablo DE RIVERO VACCARI, Stephanie ADAMCZAK, M. Ross BULLOCK, Allan LEVI, Michael Y. WANG
  • Publication number: 20200354442
    Abstract: Compositions and methods for reducing inflammation in the central nervous system (CNS) of a mammal that has been subjected to a stroke, traumatic injury to the CNS such as traumatic brain injury (TBI), spinal cord injury (SCI), or having an autoimmune or CNS disease have been developed. The compositions and methods described herein include antibodies that specifically bind to at least one component (e.g., ASC, NALP1) in a mammalian inflammasome (e.g., the NALP1 inflammasome) and have use as treatments for SCI, TBI, stroke, and autoimmune and CNS diseases in a mammal. In a rodent model of SCI, therapeutic neutralization of ASC using a polyclonal antibody that specifically binds to ASC inhibited the inflammasome, reduced caspase-1 activation, XIAP cleavage, and interleukin processing, resulting in significant tissue sparing and functional improvement. Additionally, in a rodent model of TBI, neutralization of ASC after TBI reduced caspase-1 activation and XIAP cleavage.
    Type: Application
    Filed: July 31, 2020
    Publication date: November 12, 2020
    Inventors: Robert W. KEANE, W. Dalton DIETRICH, Juan Pablo De Rivero VACCARI, Helen M. BRAMLETT
  • Publication number: 20200347124
    Abstract: The compositions and methods described herein include agents that inhibit inflammasome signaling in the mammal such as antibodies directed against inflammasome components used alone or in combination with extracellular vesicle uptake inhibitor(s). Also described herein are compositions and methods of use thereof for treating multiple sclerosis.
    Type: Application
    Filed: April 13, 2020
    Publication date: November 5, 2020
    Inventors: Robert W. KEANE, W. Dalton DIETRICH, Juan Pablo De Rivero VACCARI, Helen M. Bramlett, Roberta Brambilla
  • Publication number: 20200333358
    Abstract: The present invention provides compositions and methods for detecting components of the inflammasome in a sample from a subject as markers for brain injuries such as multiple sclerosis, stroke or traumatic brain injury. Methods of using such inflammasome markers to determine prognosis, direct treatment and monitor response to treatment for the subject with a brain injury such as multiple sclerosis, stroke, mild cognitive impairment or traumatic brain injury are also described.
    Type: Application
    Filed: September 20, 2018
    Publication date: October 22, 2020
    Inventors: Juan Pablo De Rivero VACCARI, Robert KEANE, W. Dalton DIETRICH, Helen BRAMLETT
  • Publication number: 20200308262
    Abstract: The compositions and methods described herein include methods and agents that inhibit inflammasome signaling in a mammal such as antibodies directed against inflammasome components used alone or in combination with extracellular vesicle uptake inhibitor(s) or other agents. Also described herein are compositions and methods of use thereof for treating viral-associated lung inflammation, for example lung inflammation associated with viral infections such as SARS-CoV-2.
    Type: Application
    Filed: April 23, 2020
    Publication date: October 1, 2020
    Inventors: Robert W. KEANE, W. Dalton DIETRICH, Juan Pablo De Rivero VACCARI, Roberta BRAMBILLA, Helen M. BRAMLETT
  • Patent number: 10703811
    Abstract: The compositions and methods described herein include agents that inhibit inflammasome signaling in the mammal such as antibodies directed against inflammasome components used alone or in combination with extracellular vesicle uptake inhibitor(s). Also described herein are compositions and methods of use thereof for treating multiple sclerosis.
    Type: Grant
    Filed: July 3, 2018
    Date of Patent: July 7, 2020
    Assignee: UNIVERSITY OF MIAMI
    Inventors: Robert W. Keane, W. Dalton Dietrich, Juan Pablo De Rivero Vaccari, Helen M. Bramlett, Roberta Brambilla